Merus Announces Annual General Meeting Results TORONTO, ONTARIO -- (Marketwire) -- 03/29/13 -- Merus Labs International Inc. ("Merus") (TSX:MSL)(NASDAQ:MSLI) announces the voting results from its Annual General Meeting of its shareholders held in Toronto. A total of 11.9 million common shares representing 38.9% of Merus' issued and outstanding common shares were represented at the meeting. All of the shareholders present in person at the meeting voted in favour of the items of business and the overall result of the votes, including the votes by proxy, were as follows: Resolution For Withheld ------------------------------------------ ----------- ----------- Set Number of Directors at Six 8,649,601 106,140 Elect Elie Farah as a Director 10,158,361 31,991 Elect Ahmad Doroudian as a Director 10,158,141 32,211 Elect David Guebert as a Director 7,381,996 2,808,356 Elect Robert Pollock as a Director 7,573,336 2,617,016 Elect Joseph Rus as a Director 10,158,236 32,116 Elect Timothy Sorensen as a Director 7,570,336 2,620,016 Appoint Deloitte & Touche LLP as Auditors 7,007,702 6,505 About Merus Labs International Inc. Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. Merus utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan. Contacts: Merus Labs International Inc. Elie Farah President and CEO (416) 593-3701 email@example.com
Shots Fired at Canada War Memorial, Soldier Down
Merus Announces Annual General Meeting Results
Press spacebar to pause and continue. Press esc to stop.